{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:57:13Z","timestamp":1790326633249,"version":"4.1.0"},"reference-count":26,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Obesity is a complicated chronic disease associated with a series of other conditions. A weight loss of 5\u201310% has been shown to reduce obesity-related complications and improve quality of life. The efficacy and safety of liraglutide for reducing body weight have been demonstrated in clinical trials. This study evaluated the weight loss efficacy and adverse effects of liraglutide in those with obesity in the Turkish population. Methods: This is a retrospective cohort study; the patients that were included had a body mass index (BMI) of 27 or greater with additional comorbidities or a BMI of 30 or greater, and the patients were prescribed liraglutide for obesity treatment from the tertiary private clinic between January 2022 and January 2024. Their metabolic and anthropometric parameters were recorded at the initial appointment, and their body weight and adverse effects were followed up on during therapy. Results: For the 568 patients, of whom 487 (85.6%) were female, the mean values for age, weight, and BMI were 42.37 \u00b1 10.50, 98.09 \u00b1 17.48 kg, and 35.77 \u00b1 5.45 kg\/m2, respectively. Reductions in body weight at the 4th, 8th, 12th, and 24th weeks were 6.45 \u00b1 2.32 kg, 10.66 \u00b1 3.41 kg, 15.38 \u00b1 8.30 kg, and 19 \u00b1 9.06 kg, respectively; reductions in BMI at the 4th, 8th, 12th, and 24th weeks were 2.36 \u00b1 1.00, 3.88 \u00b1 1.25, 5.36 \u00b1 1.76, and 7.09 \u00b1 2.93, respectively; and the percentages of overall body weight loss at the 4th, 8th, 12th, and 24th weeks were 6.62 \u00b1 2.1%, 10.75 \u00b1 2.71%, 14.97 \u00b1 6.8%, and 18.55 \u00b1 4.63%, respectively (all p values &lt; 0.0001). The percentage of patients who lost more than 5% and more than 10% of their initial weight was 100% at the 24th week. The most common side effect was nausea; no pancreatitis was observed. Conclusions: The results of our study indicate that liraglutide is an efficacious and safe treatment option for obesity in the Turkish population, in accordance with the findings from previous research.<\/jats:p>","DOI":"10.3390\/jcm13206121","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T07:28:35Z","timestamp":1729495715000},"page":"6121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Clinical Effectiveness of Liraglutide for Weight Management in T\u00fcrkiye: Insights from the LIRA-TR Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-9340","authenticated-orcid":false,"given":"Alihan","family":"Oral","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Biruni University, G\u00fcltepe, Halkal\u0131 Street Number: 99, 34295 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-6689","authenticated-orcid":false,"given":"Celalettin","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Biruni University, G\u00fcltepe, Halkal\u0131 Street Number: 99, 34295 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"K\u00f6se","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, 34093 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, September 15). WHO European Regional Obesity Report 2022. Available online: https:\/\/www.who.int\/europe\/publications\/i\/item\/9789289057738."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1467-789X.2007.00393.x","article-title":"Long-term weight loss effects on all cause mortality in overweight\/obese populations","volume":"8","author":"Poobalan","year":"2007","journal-title":"Obes. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jacc.2017.11.011","article-title":"Obesity: Pathophysiology and Management","volume":"71","author":"Gadde","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/oby.21653","article-title":"How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake","volume":"24","author":"Polidori","year":"2016","journal-title":"Obesity"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"European Guidelines for Obesity Management in Adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes. Facts"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000496183","article-title":"European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care","volume":"12","author":"Busetto","year":"2019","journal-title":"Obes. Facts"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1503\/cmaj.061409","article-title":"2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]","volume":"176","author":"Lau","year":"2007","journal-title":"CMAJ"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-1241.2010.02499.x","article-title":"Liraglutide: The therapeutic promise from animal models","volume":"64","author":"Knudsen","year":"2010","journal-title":"Int. J. Clin. Pract. Suppl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"Sloth","year":"2014","journal-title":"Int. J. Obes."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int. J. Obes."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int. J. Obes."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cpt.359","article-title":"Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs","volume":"100","author":"Lin","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2022). Standards of Care in Diabetes-2023 Abridged for Primary Care Providers. Clin. Diabetes, 41, 4\u201331.","DOI":"10.2337\/cd23-as01"},{"key":"ref_16","unstructured":"(2024, September 15). Association of Turkish Endocrinology and Metabolism Guidelines for the Management of Obesity. Available online: https:\/\/file.temd.org.tr\/Uploads\/publications\/guides\/documents\/20190506163904-2019tbl_kilavuz5ccdcb9e5d.pdf?a=1."},{"key":"ref_17","first-page":"8740","article-title":"A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients","volume":"27","author":"Cetiner","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int. J. Obes."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/dom.15403","article-title":"Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0\u2009mg for weight management in routine clinical practice in Switzerland (ADDRESS study)","volume":"26","author":"Schultes","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1159\/000518325","article-title":"Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland","volume":"14","author":"Haase","year":"2021","journal-title":"Obes. Facts"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.endinu.2018.09.005","article-title":"Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk","volume":"66","author":"Guler","year":"2019","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/oby.22462","article-title":"Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada","volume":"27","author":"Wharton","year":"2019","journal-title":"Obesity"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e034137","DOI":"10.1136\/bmjopen-2019-034137","article-title":"Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): Study protocol of an open-label, real-world, randomised, controlled trial","volume":"10","author":"Papamargaritis","year":"2020","journal-title":"BMJ Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e23780","DOI":"10.1097\/MD.0000000000023780","article-title":"Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia","volume":"100","author":"Park","year":"2021","journal-title":"Medicine"},{"key":"ref_25","first-page":"334","article-title":"Obezitenin Medikal Tedavisinde Liraglutide Etkinli\u011finin Ara\u015ft\u0131r\u0131lmas\u0131","volume":"13","author":"Tor","year":"2023","journal-title":"Sakarya T\u0131p. Dergisi."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/oby.23596","article-title":"Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity","volume":"31","author":"Santini","year":"2023","journal-title":"Obesity"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:13:03Z","timestamp":1760112783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":26,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13206121"],"URL":"https:\/\/doi.org\/10.3390\/jcm13206121","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}